Brief: Alterity Therapeutics Achieves Alignment With U.S. FDA On Pivotal Phase 3 Program For Ath434 In Multiple System Atrophy
09/06/2026 12:08
BRIEF-Alterity Therapeutics Achieves Alignment With U.S. FDA On Pivotal Phase 3 Program For Ath434 In Multiple System Atrophy June 9 (Reuters) - Alterity Therapeutics Ltd ATH.AX:
ALTERITY THERAPEUTICS ACHIEVES ALIGNMENT WITH U.S. FDA ON PIVOTAL PHASE 3 PROGRAM FOR ATH434 IN MULTIPLE SYSTEM ATROPHY
ALTERITY THERAPEUTICS - FDA AGREES TO PHASE 3 DESIGN INCLUDING UMSARS PART I AS PRIMARY ENDPOINT
ALTERITY THERAPEUTICS - FDA CONCURS WITH ATH434 50 MG TWICE DAILY DOSE FOR PHASE 3
ALTERITY THERAPEUTICS - PHASE 3 TRIAL ACTIVITIES ON TRACK TO INITIATE BY YEAR-END 2026
Source text: ID:nGNX1PfrCK
Further company coverage: ATH.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alterity Therapeutics
See all newsBrief: Alterity Therapeutics Achieves Alignment With U.S. FDA On Pivotal Phase 3 Program For Ath434 In Multiple System Atrophy
Brief: Alterity Therapeutics Receives Positive FDA Feedback On Ath434 Phase 3 Program
Brief: Alterity Therapeutics Says Julian Barbaczy Appointed Non-Exec Chair
Brief: Alterity Therapeutics Raises A$20.0 Million In Strategic Placement
Brief: Alterity Therapeutics Ltd Raises A$20 Million In Capital